While training in otolaryngology–head and neck surgery in Australia, Somnair Sleep co-founder and CEO Anders Sideris, Engr ...

Primary and secondary end points were demonstrated in a phase 3 trial of subcutaneous marstacimab as treatment for patients ...

Acute myeloid leukemia (AML) is an aggressive cancer affecting the blood and bone marrow that progresses rapidly, making ...

Isaralgagene civaparvovec is a “potential best-in-class gene therapy for Fabry disease,” according to analysts at H.C.

In a study of human immune cells infected with HIV, the virus that causes AIDS, scientists at Johns Hopkins Medicine say a ...

The median age of death is in the 30s, but with treatment, projected survival is improving. Today Vertex CF medicines are treating over 68,000 people with CF across more than 60 countries on six ...

AstraZeneca (NASDAQ:AZN) is one of the most active stocks to buy according to analysts. On June 16, the preliminary results ...

ACC25: Positive results with Lilly's Lp(a)-lowering drug. ... levels by an average of 93.9% over the 60 to 180-day period after treatment with the highest tested dose of 400mg. ...

They also importantly note, "The positive effects of pets, however, could be offset by risks and problems associated with them, such as allergies, parasites, physical injuries, infections ...

Person-centered therapy, also known as Rogerian therapy or client-based therapy, employs a non-authoritative approach that allows clients to take more of a lead in sessions such that, in the ...

PTC, which trumpeted the result as a resounding win, said the disparity suggests that the treatment effect with PTC518 may differ in stage 3 versus stage 2 patients.

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any breaking news developments ...